Praluent (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food& Drug Administration (FDA) has extended the approval of Praluent® (alirocumab) as an adjunct to diet and other...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news